Format

Send to

Choose Destination
See comment in PubMed Commons below
J Pathol. 2004 Apr;202(4):391-4.

TIMP-3 and endocrine therapy of breast cancer: an apoptosis connection emerges.

Author information

1
School of Biological Sciences, University of East Anglia, Norwich, NR4 7TJ, UK. Dylan.Edwards@uea.ac.uk

Abstract

The tissue inhibitors of metalloproteinases (TIMPs) control the activities of matrix metalloproteinases (MMPs) and as such, they have been recognized as potential suppressors of angiogenesis and tumour invasion and metastasis. However, TIMP-3 has several unique properties that set it apart from other TIMPs, including its ability to bind to extracellular matrix, inhibit related adamalysin metalloproteinases (ADAMs), and induce apoptosis. New data suggest that high levels of TIMP-3 mRNAs in human breast tumours are associated with success of adjuvant endocrine therapy, but not chemotherapy.

PMID:
15095265
DOI:
10.1002/path.1548
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center